OPEN ACCESS pISSN 2234-3806
eISSN 2234-3814

Cited by CrossRef (10)

  1. Hao Kong, Yancheng Liu, Sai Luo, Qiaoqiao Li, Qinglu Wang. Frequency of Calreticulin (CALR) Mutation and Its Clinical Prognostic Significance in Essential Thrombocythemia and Primary Myelofibrosis: A Meta-analysis. Intern. Med. 2016;55:1977
    https://doi.org/10.2169/internalmedicine.55.6214
  2. Renato Sampaio Tavares, Alexandre Nonino, Katia Borgia Barbosa Pagnano, Ana Clara Kneese Virgilio do Nascimento, Monika Conchon, Laura Maria Fogliatto, Vaneuza Araújo Moreira Funke, Israel Bendit, Nelma Cristina Diogo Clementino, Maria de Lourdes Lopes Ferrari Chauffaille, Wanderley Marques Bernardo, Fabio Pires de Souza Santos. Guideline on myeloproliferative neoplasms: Associacão Brasileira de Hematologia, Hemoterapia e Terapia Cellular. Hematology, Transfusion and Cell Therapy 2019;41:1
    https://doi.org/10.1016/j.htct.2019.03.001
  3. Alice Moncada, Alessandro Pancrazzi. Cellular and Molecular Aspects of Myeloproliferative Neoplasms – Part B. 2019.
    https://doi.org/10.1016/bs.ircmb.2021.02.010
  4. Anna Kabanovski, Laura Donaldson, Keyvan Koushan, Edward Margolin. CALRETICULIN MUTATION ASSOCIATED WITH BILATERAL CENTRAL RETINAL VEIN OCCLUSION IN A YOUNG WOMAN. 2023;17:389
    https://doi.org/10.1097/ICB.0000000000001200
  5. Bo Hyun Kim, Young-Uk Cho, Mi-Hyun Bae, Seongsoo Jang, Eul-Ju Seo, Hyun-Sook Chi, Yunsuk Choi, Dae-Young Kim, Jung-Hee Lee, Je-Hwan Lee, Kyoo-Hyung Lee, Young-Mi Park, Jong-Keuk Lee, Chan-Jeoung Park. JAK2 V617F, MPL, and CALR Mutations in Korean Patients with Essential Thrombocythemia and Primary Myelofibrosis. J Korean Med Sci 2015;30:882
    https://doi.org/10.3346/jkms.2015.30.7.882
  6. Yoko Kubuki, Kotaro Shide, Takuro Kameda, Takumi Yamaji, Masaaki Sekine, Ayako Kamiunten, Keiichi Akizuki, Haruko Shimoda, Yuki Tahira, Kenichi Nakamura, Hiroo Abe, Tadashi Miike, Hisayoshi Iwakiri, Yoshihiro Tahara, Mitsue Sueta, Kanna Hashimoto, Shojiro Yamamoto, Satoru Hasuike, Tomonori Hidaka, Kenji Nagata, Akira Kitanaka, Kazuya Shimoda. Differences in Hematological and Clinical Features Between Essential Thrombocythemia Cases With JAK2- or CALR-Mutations. Ann Lab Med 2017;37:159
    https://doi.org/10.3343/alm.2017.37.2.159
  7. Mi-Ae Jang, Chul Won Choi. Advances in the Diagnosis of Myeloproliferative Neoplasms. Korean J Med 2016;90:281
    https://doi.org/10.3904/kjm.2016.90.4.281
  8. Sarah Martin, Casey M. Wright, Linda M. Scott. Progenitor genotyping reveals a complex clonal architecture in a subset of CALR‐mutated myeloproliferative neoplasms. Br J Haematol 2017;177:55
    https://doi.org/10.1111/bjh.14512
  9. Sérgio Ferreira Cristina, Blanca Polo, João F. Lacerda. Somatic Mutations in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. Seminars in Hematology 2018;55:215
    https://doi.org/10.1053/j.seminhematol.2018.04.005
  10. Munazza Rashid, Rifat Zubair Ahmed, Shariq Ahmed, Muhammad Nadeem, Nuzhat Ahmed, Tahir Sultan Shamsi. Coexisting JAK2V617F and CALR Exon 9 Mutation in Essential Thrombocythemia. Indian J Hematol Blood Transfus 2016;32:112
    https://doi.org/10.1007/s12288-016-0658-y